TITAN PHARMACEUTICALS INC: Nasdaq/NYSE listing notice — Titan Pharmaceuticals receives Nasdaq notice for failure to hold annual shareholder meeting; faces potential delisting

TITAN PHARMACEUTICALS INC

Received Nasdaq notice on Jan 3, 2025 for noncompliance with listing rules due to missing annual shareholder meeting within 12 months of fiscal year end.
Has 45 days to submit a compliance plan; if accepted, Nasdaq may grant exception until June 30, 2025 to regain compliance.
Failure to regain compliance could result in delisting of common stock from Nasdaq Capital Market.
Company intends to schedule annual meeting and submit plan to regain compliance.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: shareholders
Rules: 5620(a), 5810(c)(2)(G)

Exact text from the filing

January 3, 2025, Titan Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market (“Nasdaq”) that the Company is in noncompliance with

View on SEC.gov

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a), 5810(c)(2)(G)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: shareholders
Rules: 5620(a), 5810(c)(2)(G)

Exact text from the filing

January 3, 2025, Titan Pharmaceuticals, Inc. (the “Company”) received a notice (the “Notice”) from the Nasdaq Listing Qualifications Staff of The Nasdaq Capital Market (“Nasdaq”) that the Company is in noncompliance with Listing Rules 5620(a) and 5810(c)(2)(G) as a result of its failure to hold an annual shareholder meeting within twelve months of the December 31, 2023 fiscal year end. The Notice has no immediate effect on the Company’s listing on the Nasdaq Capital Market. The Company now has 45 days to submit a plan to regain compliance. If that plan is accepted by Nasdaq, then the Company m

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001829126-25-000119

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.